Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 10, 2024
The pharmacotherapy of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, the steatohepatitis (MASH), remains a hot topic in research largely unmet need clinical practice. As first approval disease-specific drug, resmetirom, was regarded as milestone for management this common disease, comprehensive updated review aimed to highlight importance hepatic thyroid hormone (TH) receptor (THR)-β signalling treatment MASH, with special focus on resmetirom. First, genomic non-genomic actions liver-directed THR-β mediated mechanisms are summarized. has key role lipid carbohydrate metabolism; disruption leads dysmetabolism, thus promoting MASLD possibly progression MASH cirrhosis. In setting, is translated into significant association between primary hypothyroidism MASLD, confirmed by recent meta-analyses. An subclinical intrahepatic (i.e. state relatively low triiodothyronine concentrations, circulating TH concentrations within normal range) also emerging under investigation. line this, favourable results phase 3 placebo-controlled MAESTRO trials led conditional resmetirom US FDA treating adults moderate-to-advanced fibrosis. This opened new window burdensome bringing global scientific community front perspectives challenges.
Language: Английский